TFF Pharmaceuticals Cash Flow Statement

Financials in millions EUR. Fiscal year is May - April.

Millions EUR. Fiscal year is May - Apr.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct '25 Oct 31, 2025	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022	Apr '21 Apr 30, 2021
Net Income	24.06	31.81	58.41	54.33	36.59	20.5
Depreciation & Amortization	21.64	21	15.23	14.05	11.79	10.77
Other Adjustments	19.94	23.66	36.82	20.14	15.11	7.28
Change in Receivables	17.45	14.68	2.85	-22.57	-23.42	2.28
Changes in Inventories	1.87	-34.68	-66.44	-71.19	-1.32	-8.23
Changes in Other Operating Activities	-38.54	-46.57	-43.05	3.51	-8.81	-0.78
Operating Cash Flow	36.08	9.9	3.54	-1.73	29.93	48.28
Operating Cash Flow Growth	264.42%	179.82%	-	-	-38.00%	340.83%
Capital Expenditures	-19.59	-27.43	-59.26	-27.43	-11.96	-7.87
Sale of Property, Plant & Equipment	0.56	0.34	0.96	0.47	0.56	0.61
Purchases of Investments	-0.2	-0.35	-0.39	-0.47	0.49	0.15
Cash Acquisitions	-0.01	-6.65	-11.68	-1.25	-12.62	-3.07
Investing Cash Flow	-19.24	-34.09	-70.38	-28.68	-23.53	-10.19
Short-Term Debt Issued	-35.52	-46.04	18	60.93	15.83	-57.03
Net Short-Term Debt Issued (Repaid)	-35.52	-46.04	18	60.93	15.83	-57.03
Long-Term Debt Issued	131.5	141.5	133	35.1	41.03	83.06
Long-Term Debt Repaid	-97.58	-67.77	-81.49	-44.96	-58.99	-43.86
Net Long-Term Debt Issued (Repaid)	33.92	73.73	51.51	-9.86	-17.96	39.2
Common Dividends Paid	-11.56	-13.73	-13.27	-8.85	-7.64	-7.62
Other Financing Activities	8.33	-0.54	-0.04	-3.24	2.25	0.49
Financing Cash Flow	-4.84	13.42	56.21	38.98	-7.52	-24.96
Foreign Exchange Rate Adjustments	-3.19	-2.51	1.24	-3.81	4.06	-0.51
Net Cash Flow	8.82	-13.28	-9.4	4.76	2.94	12.62
Free Cash Flow	16.49	-17.53	-55.72	-29.16	17.98	40.4
Free Cash Flow Growth	-	-	-	-	-55.51%	-
FCF Margin	4.50%	-4.12%	-11.45%	-6.63%	5.94%	15.49%
Free Cash Flow Per Share	0.76	-0.81	-2.57	-1.35	0.83	1.85
Levered Free Cash Flow	-12.91	-29.29	-27.56	22.83	23.43	-3.91
Unlevered Free Cash Flow	-3.23	-44.62	-91.86	-21.68	17.16	21.61

SEC Filings: 10-K · 10-Q